The Role of Denosumab for Surgical Outcomes in Patients with Giant Cell Tumour of Bone: A Systematic Review
<i>Background:</i> The role of denosumab in patients with resectable giant cell tumour of bone remains unclear. We asked the following research question: for patients (aged ≥ 12 years) with resectable giant cell tumour of bone, what are the benefits and harms of denosumab compared with n...
Main Authors: | Abha Gupta, Lisa Durocher-Allen, Snezana Popovic, Richard Tozer, Xiaomei Yao, Michelle Ghert |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/28/2/124 |
Similar Items
-
Use of denosumab in recurrent giant cell tumour of bone: Report of two cases
by: Yuva Chandan Reddy J, et al.
Published: (2020-01-01) -
The use of denosumab in the setting of acute pathological fracture through giant cell tumour of bone
by: Wolfram Weschenfelder, et al.
Published: (2021-02-01) -
Neurological Recovery in Two Patients with Cauda Equina Syndrome Secondary to L5 Lumbar Spine Giant Cell Tumour after Treatment with Denosumab without Surgery
by: Simret Singh Randhawa, et al.
Published: (2016-10-01) -
Efficiency of denosumab in giant cell tumor of the bone
by: N N Semenov
Published: (2013-06-01) -
Recurrent giant cell tumour of the thoracic spine managed by total en bloc spondylectomy and denosumab therapy: a case report
by: Ping-Guo Duan, et al.
Published: (2020-02-01)